Brote de Ébola 2014 en África Occidental y sus riesgos para México
Palabras clave:
Virus Ébola, brote Ébola 2014, riesgo de ÉbolaResumen
La fiebre hemorrágica por el virus Ébola es una enfermedad de elevada mortalidad reportada
principalmente en África con 24 brotes hasta la fecha. Actualmente se presenta el brote más
grande y extendido del que se tiene registro. La presencia de algunos casos de Ébola en Esta-
dos Unidos y España pone en alerta máxima a las autoridades de salud de todo el mundo. Se
considera que el riesgo de que se dé un brote de esta enfermedad en México es mínimo; sin
embargo, es conveniente estar alerta ante la aparición de casos importados. Por lo anterior,
en este artículo se hace una revisión de este brote y sus implicaciones para nuestro país.
##plugins.generic.pfl.publicationFactsTitle##
##plugins.generic.pfl.reviewerProfiles## N/D
##plugins.generic.pfl.authorStatements##
Indexado: {$indexList}
-
##plugins.generic.pfl.indexedList##
- ##plugins.generic.pfl.academicSociety##
- N/D
Citas
Feldmann H, Sanchez A, Geisbert TW. Filoviridae:
Marburg and Ebola viruses. In: Knipe DM, Howley PM.
Fields virology. 6 ed. Philadelphia, Pa: Lippincott Wil-
liams & Wilkins; 2013: pp. 923-956.
Viral zone: Ebola virus molecular biology. Suiza: 2014.
[Enero de 2015]. Disponible en: http://www.viralzone.
expasy.org
Alvarez CP, Lasala F, Carrillo J, Muñiz O, Corbí AL,
Delgado R. C-type lectins DC-SING and L-SING mediate
cellular entry by Ebola virus in cis and in trans. J Virol.
; 67: 6841-6844.
Nanbo A, Masaki I, Watanabe S, Noda T, Takahashi K,
Neumann G et al. Ebolavirus is internalized into host
cells via micropinocytosis in a viral glycoprotein-depen-
dent manner. PLoS Pathog. 2010; 6: e1001121.
Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Has-
sanin A, Yaba P et al. Fruit bats as reservoirs of Ebola
virus. Nature. 2005; 438: 575-576.
Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwi-
ya, Sanchez A. Assessment of the risk of Ebola virus
transmission from bodily fluids and fomites. J Infectious
Dis. 2007; 196: S12-147.
Ströher U, West E, Bugany H, Klenk HD, Schnittler HJ
et al. Infection and activation of monocytes by Marburg
and Ebola viruses. J Virol. 2001; 75: 11025-11033.
Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR.
Tissue and cellular tropism, pathology and pathogene-
sis of Ebola and Marburg viruses. J Pathol. 2014; 235:
-174. doi: 10.1002/path.4456.
Bente D, Gren J, Strong JE, Feldmann H. Disease mod-
eling for Ebola and Marburg diseases. Disease Models
and Mechanisms. 2009; 2: 12-17.
Kortepetern MK, Bausch DG, Bray M. Basic clinical
and laboratory features of filoviral hemorrhagic fever. J
Infectious Diseases. 2011; 204: S810-S816.
Beize S, Pannetier D, Pharm D, Oestereich L, Rieger T,
Koivogui L et al. Emergence of Zaire Ebola virus disease
in guinea. N Egl J Med. 2014; 371: 1418-1425.
Gire SK, Goba A, Andersen KG, Sealfon RSG, Park DJ,
Kanneh L et al. Genomic surveillance elucidates Ebola
virus origin and transmission during the 2014 outbreak.
Science. 2014; 345: 1369-1372.
World Health Organization. Ebola response roadmap
situation report. [5 de abril 2015]. Disponible en: http://
www.who.int/csr/disease/ebola/situation-reports/en/
Chan M. Ebola virus diseases in west Africa-no early end
to the outbreak. N Engl J Med. 2014; 371: 1183-1185.
Wesolowski A, Buckee CO, Bengtsson L, Wetter E,
Lu X, Tatem AJ. Commentary: containing the Ebola
outbreak-the potential and challenge of mobile net-
work data. PLoS Curr. 2014; doi: 10.1371/currents.
outbreaks.0177e7fcf52217b8b634376e2f3efc5e.
Frieden TR, Damon I, Bell BP, Kenyon T, Nichol S.
Ebola 2014-new challenges, new global response and
responsibility. 2014; 371: 1177-1180.
Philips M, Markham A. Ebola: a failure of international
collective action. The Lancet. 2014; 384: 1181.
Dudas G, Rambaut A. Phylogenetic analysis of guinea
EBOV Ebolavirus outbreak. PLoS Curr. 2014;
doi: 10.1371/currents.outbreaks.84eefe5ce43ec9d-
c0bf0670f7b8b417d.
Centers for Disease Control and Prevention. 2014 Ebola
outbreak in Democratic Republic of the Congo. [Enero
. Disponible en: http://www.cdc.gov/vhf/ebola/
outbreaks/drc/2014-august.html
Leroy EM, Labouba I, Maganga GD, Berthet N. Ebola in
West Africa: the outbreak able to change many things. Clin
Microbiol Infect. 2014; doi: 10.1111/1469-0691.12781.
Gulland A. More health staff are needed to contain Ebola
outbreak, warns WHO. BMJ. 2014; 349: g5485.
Rivers CM, Lofgren ET, Marathe M, Eubank S, Lewis
BL. Modeling the Impact of Interventions on an Epidemic
of Ebola in Sierra Leone and Liberia. PLoS Curr. 2014;
doi: 10.1371/currents.outbreaks.fd38dd85078565450b-
be3fcd78f5ccf
Hampton T. Largest-ever outbreak of Ebola virus
disease thrusts experimental therapies, vaccines into
spotlight. JAMA. 2014; 312: 987-989.
Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC,
Bohorov O et al. Therapeutic intervention of Ebola
virus infection in rhesus macaques with the MB-003
monoclonal antibody cocktail. Sci Transl Med. 2013;
: 199ra113.
Geisbert TW, Lee ACH, Robbins M, Geisbert JB, Honko
AN, Sood V et al. Postexposure protection of non-human
primates against a lethal Ebola virus challenge with RNA
interference: a proof-of-concept study. Lancet. 2010;
: 1896-1905.
Dirección General de Epidemiología de la Secretaría de
Salud. Lineamientos estandarizados para la vigilancia
epidemiológica y diagnóstico por laboratorio de enfer-
medad por el virus del Ébola. 2014.
WHO. Technical specifications for PPE equipment to
be used by health workers providing clinical care for
patients. Disponible en: http://apps.who.int/iris/bits-
tream/10665/137411/1/WHO_EVD_Guidance_SpecP-
PE_14.1_eng.pdf?ua=1.
Feldmann H, Jones SM, Daddario-DiCaprio KM, Gies-
bert JB, Ströher U, Grolla A et al. Effective post-exposure
treatment of Ebola infection. PloS Pathog. 2007; 3 (1):
e2.
Warren TK, Wells J, Panchal RG, Stuthman KS,
Garza NL, van Tongeren SA et al. Protection against
filovirus diseases by a novel broad-spectrum nucle-
oside analogue BCX4430. Nature. 2014; 508: 402-
Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert
J, Stanley D et al. Recombinant adenovirus serotype 26
(Ad26) and Ad35 vaccine vectors bypass immunity to
Ad5 and protect nonhuman primates against ebolavirus
challenge. J Virol. 2011; 85: 4222-4233.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
© Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which allows to reproduce and modify the content if appropiate recognition to the original source is given.

